Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas.

作者信息

Aubertin Johannes, Tourpin Sophie, Janot François, Ahomadegbe Jean-Charles, Radvanyi François

出版信息

Int J Cancer. 2007 May 1;120(9):2058-9; author reply 2060. doi: 10.1002/ijc.22285.

DOI:10.1002/ijc.22285

PMID:17044022

Abstract

摘要

相似文献

Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas.

Int J Cancer. 2007 May 1;120(9):2058-9; author reply 2060. doi: 10.1002/ijc.22285.

Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas.

Int J Cancer. 2005 Oct 20;117(1):166-8. doi: 10.1002/ijc.21145.

C-deletion mutation of the p53 gene at exon 4 of codon 63 in the saliva of oral squamous cell carcinoma in central India: a preliminary study.

J Investig Clin Dent. 2010 Nov;1(2):108-13. doi: 10.1111/j.2041-1626.2010.00014.x.

[p53 alterations and HPV status in oral squamous cell carcinomas].

Verh Dtsch Ges Pathol. 1994;78:255-9.

A novel somatic FGFR3 mutation in primary lung cancer.

Oncol Rep. 2014 Mar;31(3):1219-24. doi: 10.3892/or.2014.2984. Epub 2014 Jan 20.

Patient with multiple primary carcinomas including 4 separate oral cancers: study of p53 mutations and their implications for management.

J Oral Maxillofac Surg. 2006 Nov;64(11):1672-9. doi: 10.1016/j.joms.2006.03.035.

p53 gene mutations in oral carcinomas from India.

Int J Cancer. 1996 May 3;66(3):297-300. doi: 10.1002/(SICI)1097-0215(19960503)66:3<297::AID-IJC4>3.0.CO;2-U.

Sequence variation in the I-like domain of the beta1 integrin subunit in human oral squamous cell carcinomas.

Cancer Lett. 2004 Sep 30;213(2):189-94. doi: 10.1016/j.canlet.2004.05.013.

High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay.

Oncogene. 1997 Nov 27;15(22):2667-74. doi: 10.1038/sj.onc.1201438.

Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area.

Head Neck. 2011 Dec;33(12):1758-64. doi: 10.1002/hed.21665. Epub 2011 Jan 31.

引用本文的文献

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Front Oncol. 2024 Jan 12;13:1293728. doi: 10.3389/fonc.2023.1293728. eCollection 2023.

Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting.

Biochem Soc Trans. 2018 Dec 17;46(6):1753-1770. doi: 10.1042/BST20180004. Epub 2018 Dec 13.

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.

Oncotarget. 2016 Apr 26;7(17):24252-68. doi: 10.18632/oncotarget.8132.

Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.

Cell Cycle. 2014;13(10):1551-9. doi: 10.4161/cc.28492. Epub 2014 Mar 12.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

Fibroblast growth factor signalling: from development to cancer.

Nat Rev Cancer. 2010 Feb;10(2):116-29. doi: 10.1038/nrc2780.

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.

World J Urol. 2007 Dec;25(6):581-93. doi: 10.1007/s00345-007-0213-4. Epub 2007 Oct 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验